Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06316700 · ClinicalTrials.gov registry record · NA

A Pharmacokinetic Study of a Novel Nutritional Product on Healthy Men and Women

A NA study, sponsored by Athletic Greens International.

Completed
Registry status
NA
Development phase
16
Enrollment target

NCT06316700: Completed NA study, sponsored by Athletic Greens International.

NCT06316700 is a NA study that has completed, run by Athletic Greens International. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06316700, a NA study, has completed, sponsored by Athletic Greens International.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target

Study Summary

This study is a randomized, double-blind, placebo-controlled study of N=16 apparently healthy men and women. The purpose of this study is to examine the bioavailability of a health and wellness supplement.

Primary Outcome

Zinc (ug/dl)

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Nutritional supplement

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2024-04-01
Est. Completion 2024-10-01
Phase NA
Athletic Greens International

8 total trials

What the finished NCT06316700 record still lists

NCT06316700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT06316700 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06316700 about?

NCT06316700 is a clinical study titled "A Pharmacokinetic Study of a Novel Nutritional Product on Healthy Men and Women". This study is a randomized, double-blind, placebo-controlled study of N=16 apparently healthy men and women. The purpose of this study is to examine the bioavailability of a health and wellness supplement.

What is the current status of trial NCT06316700?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2024-04-01. Estimated completion is 2024-10-01.

What interventions are being tested in trial NCT06316700?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Nutritional supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06316700?

This trial is sponsored by Athletic Greens International, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06316700's enrollment target sits among peer trials

16 1871st of 2000 higher than 120 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06316700, the US trial registry maintained by the National Library of Medicine. NCT06316700 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.